## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Quinn Tang et al.

Application No. : 10/588,602 Confirmation No. : 7130

Filed : August 7, 2006

For : RNAi THERAPEUTICS FOR TREATMENT OF EYE

**NEOVASCULARIZATION DISEASES** 

Group Art Unit : 1635

Examiner : Not Yet Assigned

New York, New York August 5, 2009

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

# INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants hereby make of record the following documents. Copies of all non-U.S. patent documents are submitted herewith.<sup>1</sup>

<sup>&</sup>lt;sup>1</sup> A completed PTO/SB/08A listing these documents is attached hereto.

Application No: 10/588,602 Docket No. INTM/019 US

Information Disclosure Statement dated August 5, 2009

# **United States Patent Publication**

 Patent No.
 Applicant
 Issue Date

 US 2002/0114784
 08-22-2002
 Li et al.

# Foreign Patent Publication

<u>Publication No.</u> <u>Publication Date</u>

WO 03/070910 08-28-2003

# Non-Patent Literature Documents

HAMMOND et al., "Post Transcriptional Gene Silencing by Double Stranded RNA," *Nature Reviews*, 2:110-119 (2001).

REICH et al., "Small Interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model," *Molecular Vision*, 9:210-216 (2003).

VALESKY et al., "Noninvasive Dynamic Fluorescence Imaging of Human Melanomas Reveals that Targeted Inhibition of bFGF or FGFR-l in Melanoma Cells Blocks Tumor Growth by Apoptosis," Molecular Medicine, 8(2):103-112 (2002).

## **REMARKS**

Applicants request that the cited documents be (1) fully considered by the Examiner during the course of examination of this application, and (2) printed on any patent issuing from this application. Additionally, applicants request that a copy of Form PTO/SB/08A, as considered and initialed by the Examiner, be returned with the next communication.

This Statement is submitted before the mailing of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97(b)(3), no fee is due in connection with this Statement. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of the fee to Deposit Account No. 06-1075, Order No. 104825-0019-101.

Respectfully submitted,

/Alla Brukman/

Jane T. Gunnison (Reg. No. 38,479) Attorney for Applicants Alla Brukman (Reg. No. 61,254) Agent for Applicants

ROPES & GRAY LLP Customer No. 1473 1211 Avenue of the Americas New York, New York 10036

Tel.: (212) 596-9000 Fax: (212) 596-9090